Google
CYTK — CYTOKINETICS INC (Healthcare >> Biotechnology)
CYTK FAQ
What is CYTK's ROE?
CYTOKINETICS INC reports a Return on Equity (ROE) of 100.37%.
What is CYTK's dividend yield?
CYTOKINETICS INC offers a dividend yield of 0.00%.
What is CYTK's Deepscope Quality Score?
Deepscope rates CYTK's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CYTK?
Deepscope's AI Timing Score for CYTK is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CYTK belong to?
CYTOKINETICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 71.48
Price
-0.81
(-1.12%)
Day Change
|
|
|---|
CYTK, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 81 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 71.48 |
| PBV / Sector |
-11.87 / 4.63
|
| Earning Per Share | -6.04 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
156.63 M
GREAT
|
| Average 1W Daily Value |
107.94 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:22 |
| Symbol | CYTK |
| Name | CYTOKINETICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 135.77 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 9,814.86 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 624 3000
Website: https://www.cytokinetics.com
Employees: 673
Sector: Healthcare >> Biotechnology
Description: Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
